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P
 
ERLECAN
 
 is a large heparan sulfate proteoglycan
with a wide tissue distribution and multiple poten-
tial functions (see Iozzo, 1998). The glycosami-
noglycan chains, located in the NH
 
2
 
-terminal domain of
the core protein, bind basic FGF-2 and have been shown
to promote the mitogenic and angiogenic activities of
FGF-2. They also interact with the basement membrane
components, laminin-1 and collagen IV, and are thought
to represent a barrier to the passage of cationic macromol-
ecules across glomerular basement membranes in the kid-
ney. The 400–450-kD core protein, composed of several
protein modules arranged in five distinct domains, binds to
a variety of small and large molecules, including FGF-7, fi-
bronectin, heparin, laminin-1, PDGF-BB, and integrins
(Fig. 1). The physiological significance of such interactions
is illustrated by the demonstration that lowering of perle-
can levels by stable expression of antisense constructs in
colon carcinoma cells depresses their FGF-7–dependent
growth, and reduces tumor growth and tumor-induced an-
giogenesis in nude mice (Sharma et al., 1998). Also, perle-
can is a strong inducer of FGF-2–dependent neovascular-
ization (Aviezer et al., 1994). These same interactions of
perlecan may well explain the finding that perlecan pro-
duced by vascular endothelial cells can inhibit prolifera-
tion and binding of FGF-2 in smooth muscle cells (Forsten
et al., 1997).
Perlecan is frequently described as a member of a small
group of basement membrane proteoglycans, the other
members being agrin and bamacan (Iozzo, 1998). While
there is no doubt that perlecan is an important molecule
within basement membranes, recent data also suggest that
it may have critical functions in other extracellular matri-
ces (Handler et al., 1997). Particularly interesting is the ex-
pression in developing and mature cartilage, raising the
possibility that it has a structural or signaling function in
cartilage development and endochondral ossification.
All these studies suggest that perlecan may not only
look like the pearls on a string structure suggested by its
rotary shadowing EM image, but in fact may be a real
pearl among extracellular matrix components: a multi-
functional macromolecule for many reasons and seasons.
That this may indeed be so, is now indicated by the conse-
quences of knocking out the perlecan gene in mice.
Costell et al. (1999) describe what happens when perle-
can expression is completely abolished. The results are
surprising, both for the severity of the abnormalities and
the specific sites that are affected. In homozygous knock-
out embryos, no abnormalities are observed before em-
bryonic day 10 (E10)
 
1
 
, but between E10 and E12, most of
the embryos die with evidence of bleeding into the peri-
cardial sac. A few animals survive, but die around birth
with severe defects in the brain and in the skeleton. The
lack of any defects before E10 is surprising because perle-
can is first expressed in two-cell embryos and increases on
the external surface of trophoectodermal cells of blasto-
cysts. Thus, it has been thought to play a role in the initial
attachment of the embryo to the uterine wall (Smith et al.,
1997). The absolutely normal Mendelian ratio of wild-
type, heterozygous, and homozygous embryos at E9.5
rules out a limiting role for perlecan during implantation.
Also, the normal appearance of most basement mem-
branes in homozygous embryos suggests that perlecan
does not have a critical role in the assembly of basement
membranes (Timpl and Brown, 1996). Perhaps the pro-
teoglycan agrin, which shares homology with perlecan, can
substitute for the absence of perlecan. Another possibility
is that collagen XVIII, also a heparan sulfate proteoglycan
component of most basement membranes, can substitute
for the loss of perlecan function (Muragaki et al., 1995;
Halfter et al., 1998).
The demise of homozygous knockouts by cardiac arrest
between E10 and E12 is associated with loss of normal
basement membrane structure around myocardial cells
and appearance of holes in the myocardium. Since base-
ment membrane structures were seen in the myocardium
of all embryos at E9.5, Costell et al. (1999) conclude that
basement membranes can form in the absence of perlecan,
but perlecan is essential for maintenance of the mechani-
cal and functional integrity of basement membranes in the
heart, particularly at a time when the intraventricular
blood pressure is thought to increase significantly. The in-
terpretation is supported by the abnormalities caused by
mutations in the perlecan homologue unc-52 in 
 
Cae-
norhabditis
 
 
 
elegans
 
. Depending on the nature of the muta-
tion, unc-52 larvae are either paralyzed and fail to develop
beyond the twofold stage or are paralyzed as adults with
disrupted myofilament–membrane attachments in body
wall muscle cells (Rogalski et al., 1993).
Costell et al. (1999) also invoke a loss of mechanical
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function to explain the abnormalities seen in embryos that
survive the cardiac crisis period: loss of basement mem-
brane structure at the surface of the developing brain with
neuroepithelial cells migrating into the surrounding mes-
enchyme. This results in lack of calvarial bone formation
and exencephaly in some embryos and neuronal ectopias
in all embryos. The defects are thought to be caused by de-
creased mechanical strength of basement membranes and
localized rupture in areas that are particularly sensitive to
the pressure within the brain vesicles. While a mechanical
basement membrane abnormality seems a reasonable ex-
planation, another possibility that needs to be considered
in future studies is that the absence of perlecan results in
increased proteolytic degradation of basement membrane
components during the remodeling of basement mem-
branes that takes place as the brain grows. Perlecan may
protect proteins against proteolytic attack and may repre-
sent an antiproteolytic shield around protease-sensitive
components (such as nidogen) in basement membranes
(Gupta-Bansal et al., 1995).
Surprisingly, all homozygous embryos surviving to birth
also show severe skeletal defects with short axial and limb
bones, cleft palate, and striking abnormalities in the
growth plates of long bones. Although perlecan is ex-
pressed in developing cartilage and can promote differen-
tiation of chondrocytes in culture (French et al., 1999)
such an essential role for perlecan in cartilage growth and
endochondral ossification is quite unexpected. In normal
growth plates, chondrocytes are arranged into zones of
resting, proliferating, and mature (hypertrophic) cells, and
the cellular activities within each zone and the transitions
between them are regulated by key signaling molecules. In
perlecan knockouts, the proliferating zone is disorganized,
the hypertrophic zone shows signs of increased levels of
synthesis of several matrix molecules, and is frequently
separated from the proliferative zone. Ossification below
 
the growth plate appears to extend as much radially as it
does along the longitudinal axis of long bones.
The authors suggest that perlecan protects the extracel-
lular matrix of cartilage by inactivating matrix proteases or
masking/protecting proteins against proteolytic degrada-
tion (Costell et al., 1999). A role for perlecan in modu-
lating important signaling pathways that regulate chon-
drocyte proliferation and hypertrophy is also a strong
possibility and needs to be considered in future studies.
FGFR3 is a negative regulator of chondrocyte prolifera-
tion and hypertrophy, and perlecan may modulate its ac-
tivity by sequestering FGF ligands (Deng et al., 1996). Fur-
thermore, Indian hedgehog is produced by cells defining
the transition between proliferating and hypertrophic
chondrocytes, and it controls the expression of parathy-
roid hormone-related peptide (PTHrP), a negative regula-
tor of hypertrophy, through a feedback loop that involves
Patched-expressing cells in the surrounding perichon-
drium (Vortkamp et al., 1996). Identification of a gene
(
 
tout-velu
 
) in 
 
Drosophila
 
 that promotes the diffusion of
hedgehog over several cell diameters as a homologue of a
human glycosyl transferase, raises the very interesting pos-
sibility that perlecan may play a role in diffusion of Indian
hedgehog in the growth plates of long bones (Bellaiche et al.,
1998; Lind et al., 1998). The glycosyl transferase homo-
logue of tout-velu (EXT1) is involved in the synthesis of
heparan sulfate proteoglycans; mutations in EXT1 cause
the formation of multiple cartilage-capped bone tumors
around growth plates (exostoses) in affected individuals
(Ahn et al., 1995). Heparan sulfate proteoglycans may,
therefore, be critical for normal diffusion of sonic or In-
dian hedgehog.
Further studies of these and other possibilities would
benefit from the generation of conditional knockouts to
circumvent the bottleneck of embryonic lethality. Such
conditional knockouts would also be extremely useful in
Figure 1. Structure of perlecan (see
Iozzo, 1998). Several distinct protein
modules are organized in five domains
(I–V). Domain I contains the gly-
cosaminoglycan side chains (indicated
by wavy lines). Note that in domain IV
only six of the 21 Ig-like repeats are
shown. 
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analyses of the role of perlecan in promoting the growth
and invasion of tumors, its role in glomerular filtration in
the kidney, and its angiogenesis promoting activities. With
a variety of cell-specific promoters available, both for vas-
cular endothelial cells and proliferating and hypertrophic
chondrocytes, generation of conditional perlecan mutants
should be relatively straightforward. We look forward to
further exciting news from the perlecan front.
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